Neurology Edition: Top Headlines for Week of April 18, 2022

In this week’s edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings.

Read the full coverage here:

FDA approves oral anticonvulsant

New drug improved tic severity in children with Tourette syndrome

Vitamin D levels not associated with adverse outcomes in European MS patients

Zolpidem may be effective for prolonged disorders of consciousness

Amygdala overgrowth begins in first year of life in infants with ASD

References:

Press Release

Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida.

Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896

Disclosures: Please see each study for relevant financial disclosures.